BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26205665)

  • 21. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.
    Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
    J Med Assoc Thai; 2011 Jul; 94(7):863-70. PubMed ID: 21774295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.
    Munoz-Price LS; Zembower T; Penugonda S; Schreckenberger P; Lavin MA; Welbel S; Vais D; Baig M; Mohapatra S; Quinn JP; Weinstein RA
    Infect Control Hosp Epidemiol; 2010 Oct; 31(10):1057-62. PubMed ID: 20715975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections.
    Baran G; Erbay A; Bodur H; Ongürü P; Akinci E; Balaban N; Cevik MA
    Int J Infect Dis; 2008 Jan; 12(1):16-21. PubMed ID: 17513154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.
    Tal-Jasper R; Katz DE; Amrami N; Ravid D; Avivi D; Zaidenstein R; Lazarovitch T; Dadon M; Kaye KS; Marchaim D
    Antimicrob Agents Chemother; 2016 May; 60(5):3127-31. PubMed ID: 26883694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.
    Du X; Xu X; Yao J; Deng K; Chen S; Shen Z; Yang L; Feng G
    Am J Infect Control; 2019 Sep; 47(9):1140-1145. PubMed ID: 31003750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active surveillance for carbapenem-resistant Acinetobacter baumannii in a medical intensive care unit: Can it predict and reduce subsequent infections and the use of colistin?
    An JH; Kim YH; Moon JE; Jeong JH; Kim SH; Kang SJ; Park KH; Jung SI; Jang HC
    Am J Infect Control; 2017 Jun; 45(6):667-672. PubMed ID: 28242072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study.
    Thatrimontrichai A; Techato C; Dissaneevate S; Janjindamai W; Maneenil G; Kritsaneepaiboon S; Tanaanantarak P
    J Infect Chemother; 2016 Jul; 22(7):444-9. PubMed ID: 27229539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case-case-control study.
    Thatrimontrichai A; Apisarnthanarak A; Chanvitan P; Janjindamai W; Dissaneevate S; Maneenil G
    Pediatr Infect Dis J; 2013 Feb; 32(2):140-5. PubMed ID: 22935872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk and Prognostic Factors for Multidrug-Resistant Acinetobacter Baumannii Complex Bacteremia: A Retrospective Study in a Tertiary Hospital of West China.
    Liu Q; Li W; Du X; Li W; Zhong T; Tang Y; Feng Y; Tao C; Xie Y
    PLoS One; 2015; 10(6):e0130701. PubMed ID: 26083415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality.
    Hernández-Torres A; García-Vázquez E; Gómez J; Canteras M; Ruiz J; Yagüe G
    Med Clin (Barc); 2012 May; 138(15):650-5. PubMed ID: 22093403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.
    Lee NY; Lee HC; Ko NY; Chang CM; Shih HI; Wu CJ; Ko WC
    Infect Control Hosp Epidemiol; 2007 Jun; 28(6):713-9. PubMed ID: 17520546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbapenem-resistant Acinetobacter baumannii Bacteremia in Liver Transplant Recipients.
    Kim YJ; Kim SI; Lee YD; Choi HJ; Choi JY; Yoon SK; You YK; Kim DG
    Transplant Proc; 2018 May; 50(4):1132-1135. PubMed ID: 29731080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.
    Lemos EV; de la Hoz FP; Einarson TR; McGhan WF; Quevedo E; Castañeda C; Kawai K
    Clin Microbiol Infect; 2014 May; 20(5):416-23. PubMed ID: 24131374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.
    Lee YT; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Yang YS
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.
    Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
    Ng TM; Teng CB; Lye DC; Apisarnthanarak A
    Infect Control Hosp Epidemiol; 2014 Jan; 35(1):49-55. PubMed ID: 24334798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the computerized tomography scanner in the cross-transmission of carbapenem-resistant Acinetobacter baumannii between hospitalized patients.
    Dadon Z; Ben-Chetrit E; Benjaminov O; Taha L; Wiener-Well Y; Belman D; Levin PD
    Clin Microbiol Infect; 2021 Apr; 27(4):635.e1-635.e4. PubMed ID: 33421579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia.
    Chusri S; Chongsuvivatwong V; Silpapojakul K; Singkhamanan K; Hortiwakul T; Charernmak B; Doi Y
    J Microbiol Immunol Infect; 2019 Oct; 52(5):796-806. PubMed ID: 31031096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific.
    Le Hello S; Falcot V; Lacassin F; Mikulski M; Baumann F
    Scand J Infect Dis; 2010 Dec; 42(11-12):821-6. PubMed ID: 20560868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with Acinetobacter baumannii bacteremia.
    Lan M; Dongmei K; Guodong S; Haifeng Y; Guofeng C; Mengting C; Xiaoyun F
    BMC Infect Dis; 2024 Apr; 24(1):448. PubMed ID: 38671347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.